These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19490555)

  • 1. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
    Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
    Taylor DC; Pandya A; Thompson D; Chu P; Graff J; Shepherd J; Wenger N; Greten H; Carmena R; Drummond M; Weinstein MC
    Eur J Health Econ; 2009 Jul; 10(3):255-65. PubMed ID: 18800232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
    Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Landau W
    Neurology; 2009 Sep; 73(10):817; author reply 818. PubMed ID: 19738180
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
    Ovbiagele B; Goldstein LB; Amarenco P; Messig M; Sillesen H; Callahan A; Hennerici MG; Zivin J; Welch KM;
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):778-84. PubMed ID: 24582273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.